Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 887 results for score

  1. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    HealthTech guidance
    Published
    25 July 2011
    View recommendations

    Sections for HTG268

  2. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.

    Technology appraisal guidance
    Published
    3 October 2018
    View recommendations

    Sections for TA543

  3. Extracorporeal shockwave therapy for refractory tennis elbow (HTG201)

    Evidence-based recommendations on extracorporeal shockwave therapy for refractory tennis elbow. This involves using a machine to deliver sound waves to the painful area to stimulate healing.

    HealthTech guidance
    Published
    26 August 2009
    View recommendations

    Sections for HTG201

  4. Minimally invasive video‑assisted parathyroidectomy (HTG350)

    Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.

    HealthTech guidance
    Published
    23 August 2014
    View recommendations

    Sections for HTG350

  5. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.

    Highly specialised technologies guidance
    Published
    1 March 2023
    View recommendations

    Sections for HST23

  6. Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more.

    Technology appraisal guidance
    Published
    25 November 2020
    View recommendations

    Sections for TA661

  7. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

    NICE guideline
    Published
    17 November 2021
    View recommendations

    Sections for NG208

  8. In patients with negative MRI (Likert score 1 or 2), what is the next best diagnostic investigation to rule out clinically significant prostate cancer? What is the diagnostic accuracy of transperineal mapping biopsy compared with transperineal non-mapping biopsy in the diagnosis of clinically significant prostate cancer?

    ID NG131/7 Question In patients with negative MRI (Likert score 1 or 2), what is the next best diagnostic investigation to rule out...

    Research recommendation
    Published
    25 October 2019

  9. Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

    Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.

    Technology appraisal guidance
    Last updated
    24 August 2016
    View recommendations

    Sections for TA391

  10. Percutaneous laser revascularisation for refractory angina pectoris (HTG193)

    Evidence-based recommendations on percutaneous laser revascularisation for refractory angina pectoris. This involves inserting a catheter into major vessels of the groin, which is advanced to the heart, to drill holes on the heart muscle using a laser beam.

    HealthTech guidance
    Published
    27 May 2009
    View recommendations

    Sections for HTG193

  11. Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)

    NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .

    Medtech innovation briefing
    Published
    30 July 2018

  12. Percutaneous tibial nerve stimulation for faecal incontinence (HTG263)

    Evidence-based recommendations on percutaneous tibial nerve stimulation (PTNS) for faecal incontinence. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current through the needle to the nerves that control bowel function.

    HealthTech guidance
    Published
    25 May 2011
    View recommendations

    Sections for HTG263

  13. Transcutaneous microwave ablation for severe primary axillary hyperhidrosis (HTG458)

    Evidence-based recommendations on transcutaneous microwave ablation for severe primary axillary hyperhidrosis in adults. This involves using microwaves to destroy sweat glands in the armpit.

    HealthTech guidance
    Published
    20 December 2017
    View recommendations

    Sections for HTG458

  14. SYNE-COV for predicting COVID-19 outcomes (MIB264)

    NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .

    Medtech innovation briefing
    Published
    15 June 2021

  15. Stroke in adults (QS2)

    This quality standard covers diagnosing and managing stroke in adults (over 16). It includes diagnosis, initial management, acute-phase care, rehabilitation and long-term support for people with stroke. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    12 April 2016
    View quality statements

    Sections for QS2